Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Type of diabetes mellitus: Does it matter to the clinician?

Hoogwerf BJ.

Cleve Clin J Med. 2020 Feb;87(2):100-108. doi: 10.3949/ccjm.87a.19020.

2.

Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes.

Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL.

Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017.

3.

Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.

Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ.

J Investig Med. 2018 Mar;66(3):661-668. doi: 10.1136/jim-2017-000609. Epub 2017 Nov 21.

PMID:
29167192
4.

Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes.

Connelly MA, Otvos JD, Zhang Q, Zhang S, Antalis CJ, Chang AM, Hoogwerf BJ.

Biomark Med. 2017 Nov;11(11):991-1001. doi: 10.2217/bmm-2017-0112.

PMID:
29160108
5.

Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control.

Alatorre CI, Hoogwerf BJ, Deeg MA, Nelson DR, Hunter TM, Ng WT, Rekhter MD.

Curr Med Res Opin. 2018 Feb;34(2):337-343. doi: 10.1080/03007995.2017.1396969. Epub 2017 Nov 24.

PMID:
29065729
6.

Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.

Bae JP, Duan R, Fu H, Hoogwerf BJ.

Clin Ther. 2017 Sep;39(9):1790-1798.e7. doi: 10.1016/j.clinthera.2017.07.037. Epub 2017 Aug 7.

7.

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.

Orchard TJ, Cariou B, Connelly MA, Otvos JD, Zhang S, Antalis CJ, Ivanyi T, Hoogwerf BJ.

Cardiovasc Diabetol. 2017 Jun 6;16(1):73. doi: 10.1186/s12933-017-0555-1.

8.

Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.

Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A.

Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22.

PMID:
28417532
9.

Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.

Cusi K, Sanyal AJ, Zhang S, Hoogwerf BJ, Chang AM, Jacober SJ, Bue-Valleskey JM, Higdon AN, Bastyr EJ 3rd, Haupt A, Hartman ML.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:50-58. doi: 10.1111/dom.12751.

PMID:
27723227
10.

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.

Ginsberg H, Cariou B, Orchard T, Chen L, Luo J, Bastyr EJ 3rd, Bue-Valleskey J, Chang AM, Ivanyi T, Jacober SJ, Hoogwerf BJ.

Diabetes Obes Metab. 2016 Nov;18(11):1089-1092. doi: 10.1111/dom.12754. Epub 2016 Sep 14.

PMID:
27486125
11.

Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.

Hoogwerf BJ, Manner DH, Fu H, Moscarelli E, Gaydos BL, Heine RJ.

Diabetes Care. 2016 Aug;39 Suppl 2:S219-27. doi: 10.2337/dcS15-3025. Review.

PMID:
27440836
12.

Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.

Garg S, Selam JL, Bhargava A, Schloot N, Luo J, Zhang Q, Jacobson JG, Hoogwerf BJ.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:43-49. doi: 10.1111/dom.12740.

PMID:
27393722
13.

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.

Hoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y.

Cardiovasc Diabetol. 2016 May 17;15:78. doi: 10.1186/s12933-016-0393-6.

14.

Risk factors for 30-day readmission following hypoglycemia-related emergency room and inpatient admissions.

Emons MF, Bae JP, Hoogwerf BJ, Kindermann SL, Taylor RJ, Nathanson BH.

BMJ Open Diabetes Res Care. 2016 Apr 4;4(1):e000160. doi: 10.1136/bmjdrc-2015-000160. eCollection 2016.

15.

Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011.

Bae JP, Lage MJ, Mo D, Nelson DR, Hoogwerf BJ.

J Diabetes Complications. 2016 Mar;30(2):212-20. doi: 10.1016/j.jdiacomp.2015.11.016. Epub 2015 Nov 17.

16.

Frederick C. Goetz, MD: a profile of the intersection among science, the fine arts, and education.

Hoogwerf BJ, Kendall DM, Seaquist ER.

Diabetes Care. 2014 Sep;37(9):2419-23. doi: 10.2337/dc14-0283. No abstract available.

PMID:
25147251
17.

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group.

Diabetes Care. 2014 Oct;37(10):2763-73. doi: 10.2337/dc14-0876. Epub 2014 Jul 10.

PMID:
25011946
18.

Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.

Tuttle KR, Heilmann C, Hoogwerf BJ, Brown C, Anderson PW.

Am J Kidney Dis. 2013 Aug;62(2):396-8. doi: 10.1053/j.ajkd.2013.03.026. Epub 2013 May 16. No abstract available.

PMID:
23684754
19.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G.

Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.

PMID:
23141817
20.

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.

Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB.

Int J Clin Pract. 2012 Dec;66(12):1147-57. doi: 10.1111/ijcp.12032. Epub 2012 Oct 14. Review.

21.

Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, Fonseca V.

Endocr Pract. 2012 Sep-Oct;18(5):700-11. doi: 10.4158/EP11367.OR.

PMID:
22982784
22.

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.

Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.

Postgrad Med. 2012 Jul;124(4):33-40. doi: 10.3810/pgm.2012.07.2568.

PMID:
22913892
23.

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ.

Clin Ther. 2012 Jun;34(6):1247-1258.e22. doi: 10.1016/j.clinthera.2012.04.013. Epub 2012 May 18. Review. Erratum in: Clin Ther. 2014 Feb 1;36(2):307-8.

24.

Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.

Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.

Endocr Pract. 2012 Mar-Apr;18(2):227-37. doi: 10.4158/EP11306.OR.

PMID:
22446132
25.

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ.

Diabetes Care. 2012 May;35(5):955-8. doi: 10.2337/dc11-1434. Epub 2012 Mar 19.

26.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x. Epub 2012 Mar 8.

PMID:
22321776
27.

Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.

Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R.

J Med Econ. 2011;14(6):705-8. doi: 10.3111/13696998.2011.613505. Epub 2011 Sep 5.

PMID:
21892855
28.

Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study.

McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ.

Thyroid. 2011 Aug;21(8):837-43. doi: 10.1089/thy.2010.0298. Epub 2011 Jul 11.

PMID:
21745107
29.

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.

Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L.

Cardiovasc Diabetol. 2011 Mar 16;10:22. doi: 10.1186/1475-2840-10-22.

30.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300. Epub 2010 Dec 6.

PMID:
21138825
31.
32.

Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study.

Zhang JP, Pozuelo L, Brennan DM, Hoar B, Hoogwerf BJ.

Prev Cardiol. 2010 Summer;13(3):122-9. doi: 10.1111/j.1751-7141.2009.00061.x.

33.

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group.

Diabetes Care. 2010 Jul;33(7):1578-84. doi: 10.2337/dc10-0125. Epub 2010 Mar 9.

34.

High school body mass index and body mass index at entry to a cardiac disease risk prevention clinic and the association to all-cause mortality and coronary heart disease: a PreCIS database study.

Gambino KK, Zumpano J, Brennan DM, Hoogwerf BJ.

J Cardiovasc Nurs. 2010 Mar-Apr;25(2):99-105. doi: 10.1097/JCN.0b013e3181bdbc4c.

PMID:
20168189
35.

Renin-angiotensin system blockade and cardiovascular and renal protection.

Hoogwerf BJ.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):30A-5A. doi: 10.1016/j.amjcard.2009.10.009. Review.

PMID:
20102971
36.

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.

Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J.

Cardiovasc Diabetol. 2010 Jan 28;9:6. doi: 10.1186/1475-2840-9-6.

37.

The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study.

Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ.

Obesity (Silver Spring). 2010 Sep;18(9):1836-44. doi: 10.1038/oby.2009.453. Epub 2009 Dec 24.

38.

Clinical utility of waist circumference in predicting all-cause mortality in a preventive cardiology clinic population: a PreCIS Database Study.

Bajaj HS, Brennan DM, Hoogwerf BJ, Doshi KB, Kashyap SR.

Obesity (Silver Spring). 2009 Aug;17(8):1615-20. doi: 10.1038/oby.2009.44. Epub 2009 Mar 5.

39.

Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD.

Hoogwerf BJ; Action to Control Cardiovascular Risk in; Diabetes Study Group.

Cleve Clin J Med. 2008 Oct;75(10):729-37. Review.

40.

Managing type 2 diabetes: going beyond glycemic control.

Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO.

J Manag Care Pharm. 2008 Jun;14(5 Suppl B):s2-19.

PMID:
18597582
42.

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.

Shishehbor MH, Oliveira LP, Lauer MS, Sprecher DL, Wolski K, Cho L, Hoogwerf BJ, Hazen SL.

Am J Cardiol. 2008 Jun 15;101(12):1741-6. doi: 10.1016/j.amjcard.2008.02.060. Epub 2008 Apr 9.

43.

The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study.

Davidson MB, Hu T, Sain G, Hoar B, Stevenson C, Hoogwerf BJ.

Diabetes Obes Metab. 2009 Feb;11(2):118-22. doi: 10.1111/j.1463-1326.2008.00912.x. Epub 2008 Jun 1.

PMID:
18518894
44.

All-cause mortality risk predictors in a preventive cardiology clinic cohort-examining diabetes and individual metabolic syndrome criteria: a PRECIS database study.

Doshi KB, Kashyap SR, Brennan DM, Hoar BM, Cho L, Hoogwerf BJ.

Diabetes Obes Metab. 2009 Feb;11(2):102-8. doi: 10.1111/j.1463-1326.2008.00908.x. Epub 2008 May 20.

PMID:
18494803
45.
46.

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.

American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML.

Diabetes Care. 2008 Jan;31 Suppl 1:S61-78. doi: 10.2337/dc08-S061. No abstract available. Erratum in: Diabetes Care. 2010 Aug;33(8):1911.

PMID:
18165339
47.

Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study.

Ioachimescu AG, Brennan DM, Hoar BM, Kashyap SR, Hoogwerf BJ.

Diabet Med. 2007 Dec;24(12):1369-74. Epub 2007 Nov 1.

PMID:
17976199
48.

Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus.

Neuser D, Benson A, Brückner A, Goldberg RB, Hoogwerf BJ, Petzinna D.

Clin Drug Investig. 2005;25(9):579-87.

PMID:
17532702
49.

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896.

PMID:
17404349
50.

Diabetes mellitus--overview.

Hoogwerf BJ, Sferra J, Donley BG.

Foot Ankle Clin. 2006 Dec;11(4):703-15. Review.

PMID:
17097511

Supplemental Content

Loading ...
Support Center